APPENDICES. A systematic review and economic model of the ...

310
Appendix 12
Study Intervention Participants Outcomes
Core symptoms
Abbreviated ACTRS (teachers, counsellors)
Inclusion criteria
Inclusion criteria are not explicitly reported
Reference
Pelham et al., 1990 78
Co-existent problems
Appropriate/inappropriate behaviour ratings:
following rules, positive peer behaviours, noncompliance,
conduct problems, negative
verbalisations (counsellors)
Rule-following behaviour (teachers)
Diagnostic criteria
DSM-III
Arm 1
MPH plus non-drug intervention
Standard; 10 mg administered twice
daily (a.m., noon); broad spectrum
behaviour modification intervention
(Administered by parent and
programme staff)
Source
AHRQ Report
Number
Total randomised = 22 (male = 22)
No withdrawals reported
Setting
USA
(STP)
Educational performance
Arithmetic drill: number of questions
attempted, percentage completed correctly
Timed reading task: number of questions
attempted, percentage completed correctly
Randomisation procedure:
Note that placebo, standard MPH, sustained-release MPH and
DEX were randomised over single days whereas PEM was
randomised in triplets of days, with only the last two days of the
three being used to record data
Arm 2
MPH plus non-drug intervention
Sustained release 20 mg administered
once daily with midday placebo;
broad spectrum behaviour
modification intervention
(Administered by parent and
programme staff)
Design
Crossover trial
Psychological function
Continous Performance Task: errors of
commission, errors of omission
Age
10.39 years (mean); 8.08–13.17 years (range); 1.38 years (SD)
Duration
STP: 8 weeks; drug
treatment period:
6 1 –
2 weeks; baseline
assessment period:
1 1 –
2 weeks
Depression or anxiety
Not reported
Quality of life
Not reported.
IQ
105.68 (mean)
Co-morbid disorders
ODD: n = 9/22; CD: n = 4/22; learning disability suggested:
n = 13/22; Concurrent seizure disorder: n = 1/22.
Diagnostic subtypes
Not reported
Arm 3
DEX plus non-drug intervention
Sustained release 10 mg administered
once daily (a.m.) with midday
placebo; broad spectrum behaviour
modification intervention
(Administered by parent and
programme staff)
Adverse events
Side-effects checklists (parents, teachers,
counsellors)
Additional information
No relevant information reported
Purpose
To evaluate the relative
efficacy of comparable
doses of the three longacting
forms of
stimulant – PEM,
dextroamphetamine
and MPH – with the
standard MPH
preparation
Additional outcomes
Daily report cards: percentage of days child
reached academic and behavioural criteria
Arm 4
PEM plus non-drug intervention
56.25 mg administered once daily
(a.m.) with midday placebo; broad
spectrum behaviour modification
intervention
(Administered by parent and
programme staff)